Novartis Capital Corporation prices $5.5 billion four-tranche notes offering
The Novartis AG subsidiary finalized rates, prices and amounts for notes due 2029, 2032, 2034 and 2037 in a filing dated November 9, 2026.
Novartis Capital Corporation finalized the terms of its four-tranche notes offering in a prospectus supplement dated November 9, 2026, filling in pricing that had been left blank in its preliminary filing of the same date.
The company priced $500,000,000 of 4.900% notes due November 12, 2029 at an issue price of 99.846%, $1,500,000,000 of 5.200% notes due February 12, 2032 at 99.945%, $1,750,000,000 of 5.300% notes due February 12, 2034 at 99.433%, and $1,750,000,000 of 5.500% notes due February 12, 2037 at 99.576%1. The notes are fully and unconditionally guaranteed by Novartis AG1.
Interest on the 2029 notes will be paid each May 12 and November 12, commencing May 12, 2027, while interest on the 2032, 2034 and 2037 notes will be paid each February 12 and August 12, commencing February 12, 20271. The underwriters expect to deliver the notes in book-entry form through DTC, Clearstream and Euroclear, against payment in New York on or about November 12, 20261.
Barclays, BofA Securities, Goldman Sachs & Co. LLC and Societe Generale, along with Citigroup, HSBC, Mizuho and J.P. Morgan, are listed as joint book-running managers, with BNP Paribas and Deutsche Bank Securities named as co-managers1.
Novartis estimated net proceeds of approximately $5.46 billion after underwriting discounts and expenses, and intends to use the proceeds for general corporate purposes outside of Switzerland, including refinancing existing long- and short-term indebtedness1.
The notes carry optional redemption features. Prior to the applicable par call dates, Novartis Capital Corporation may redeem the notes at a make-whole price using the Treasury Rate plus 10 basis points for the 2029, 2032 and 2034 notes and 15 basis points for the 2037 notes, or at 100% of principal, whichever is greater1.
As of the filing date, neither Novartis AG nor Novartis Capital Corporation had any secured indebtedness1. Novartis Capital Corporation is a wholly-owned indirect subsidiary of Novartis AG, incorporated in Delaware on July 23, 20081.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.